Twist Bioscience (NASDAQ:TWST) Shares Gap Up – What’s Next?

Twist Bioscience Corporation (NASDAQ:TWST)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $41.07, but opened at $43.46. Twist Bioscience shares last traded at $46.88, with a volume of 840,163 shares trading hands.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Robert W. Baird set a $50.00 price objective on Twist Bioscience in a research report on Tuesday. Barclays boosted their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Finally, Evercore ISI boosted their price target on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday. Seven analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $45.88.

Twist Bioscience Trading Up 3.9%

The company has a current ratio of 3.78, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03. The stock has a fifty day simple moving average of $36.23 and a 200 day simple moving average of $31.84.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The firm had revenue of $103.70 million during the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The firm’s revenue for the quarter was up 16.9% on a year-over-year basis. As a group, analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other news, CFO Adam Laponis sold 3,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $40.00, for a total value of $120,000.00. Following the completion of the sale, the chief financial officer owned 137,031 shares in the company, valued at approximately $5,481,240. The trade was a 2.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Emily M. Leproust sold 1,605 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $34.56, for a total transaction of $55,468.80. Following the completion of the sale, the chief executive officer owned 874,313 shares of the company’s stock, valued at approximately $30,216,257.28. This trade represents a 0.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 7,940 shares of company stock valued at $292,643 over the last quarter. Company insiders own 3.08% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after buying an additional 302 shares during the period. D.A. Davidson & CO. raised its stake in Twist Bioscience by 1.2% during the 4th quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after acquiring an additional 305 shares in the last quarter. CWM LLC increased its position in shares of Twist Bioscience by 9.4% during the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after purchasing an additional 407 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after buying an additional 442 shares during the last quarter. Finally, California State Teachers Retirement System boosted its stake in Twist Bioscience by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after purchasing an additional 442 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.